AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29762273 — intervention group
Group type: EXPERIMENTAL
Intervention: More activated patients
Number of subjects: 606
Study 28443338 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with a certified child passenger safety (CPS) technician
Number of subjects: 189
Study 28443338 — intervention group
Group type: COMPARATOR
Intervention: Standard care with CSS safety brochure
Number of subjects: 189
Study 26290867 — intervention group
Group type: EXPERIMENTAL
Intervention: LC n‐3 PUFAs (2.52 g/day)
Number of subjects: 0
Study 26290867 — intervention group
Group type: COMPARATOR
Intervention: Placebo (canola oil)
Number of subjects: 0
Study 24385636 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 1912
Study 24385636 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster-memory training
Number of subjects: 1912
Study 24385636 — intervention group
Group type: COMPARATOR
Intervention: No-contact Control group
Number of subjects: 1912
Study 20840564 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-lying hip abduction training with external loading (10 repetition maximum)
Number of subjects: 31
Study 20840564 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-lying hip abduction training without external loading (weight of the leg)
Number of subjects: 31
Study 18424600 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose almonds (73 +/- 3 g/d)
Number of subjects: 27
Study 18424600 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose almonds plus half-dose muffins
Number of subjects: 27
Study 18424600 — intervention group
Group type: COMPARATOR
Intervention: Full-dose muffins (control)
Number of subjects: 27
Study 16644224 — intervention group
Group type: EXPERIMENTAL
Intervention: ACI‐C (type I/III collagen membrane)
Number of subjects: 68
Study 16644224 — intervention group
Group type: COMPARATOR
Intervention: ACI‐P (periosteal cover)
Number of subjects: 68
Study 12600847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean beef diet
Number of subjects: 0
Study 12600847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean fish diet
Number of subjects: 0
Study 12600847 — intervention group
Group type: EXPERIMENTAL
Intervention: Poultry diet
Number of subjects: 0
Study 10839090 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimbus III APMRS (Huntleigh Healthcare Ltd)
Number of subjects: 32
Study 10839090 — intervention group
Group type: COMPARATOR
Intervention: Control surfaces (mainly APMRS; Pegasus Airwave, Pegasus Egerton in hospital; AlphaXcell, Huntleigh Healthcare Ltd in residential care)
Number of subjects: 32
Study 10839090 — intervention group
Group type: COMPARATOR
Intervention: Control surfaces
Number of subjects: 32
Study 8780944 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP1) at dosages of 0.5 mg/kg, 1.0 mg/kg, and 2.0 mg/kg body weight
Number of subjects: 34
Study 8780944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8780944 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated group)
Number of subjects: 34
Study 1623900 — intervention group
Group type: EXPERIMENTAL
Intervention: dexfenfluramine (30 mg daily)
Number of subjects: 30
Study 1623900 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 6597721 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin (3 X 50 mg daily)
Number of subjects: 9
Study 6597721 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen (2 X 150 mg daily)
Number of subjects: 9
Study 6597721 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 X daily)
Number of subjects: 9
Study 31315700 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise measures to ensure sputum quality (instructions by a study nurse, sputum induction if necessary)
Number of subjects: 980
Study 31315700 — intervention group
Group type: COMPARATOR
Intervention: Standard sputum collection without observation (control group)
Number of subjects: 980
Study 29299957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer Home-Life Intervention
Number of subjects: 242
Study 29299957 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 242
Study 26954267 — intervention group
Group type: EXPERIMENTAL
Intervention: JASP+EMT+SGD
Number of subjects: 61
Study 26954267 — intervention group
Group type: COMPARATOR
Intervention: JASP+EMT
Number of subjects: 61
Study 25387780 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 2439
Study 25387780 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 2439
Study 22252798 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 0
Study 19337933 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological intervention 1
Number of subjects: 96
Study 19337933 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological intervention 2
Number of subjects: 96
Study 19337933 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific training)
Number of subjects: 96
Study 19337933 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall neuropsychological test results
Number of subjects: 96
Study 19337933 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically relevant neuropsychological deficits
Number of subjects: 96
Study 17717679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fly-wheel ergometer (FWE)
Number of subjects: 29
Study 17717679 — intervention group
Group type: COMPARATOR
Intervention: Standard knee extensor training equipment
Number of subjects: 29
Study 15105030 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamarind supplementation for 3 weeks
Number of subjects: 30
Study 15105030 — intervention group
Group type: COMPARATOR
Intervention: Defluoridated water (control) for 3 weeks
Number of subjects: 30
Study 12470198 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 mg/day for 6 weeks)
Number of subjects: 32
Study 12470198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9814508 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH 200 IU
Number of subjects: 16
Study 9814508 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH 100 IU
Number of subjects: 16
Study 9814508 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 16
Study 7808991 — intervention group
Group type: EXPERIMENTAL
Intervention: Four months Rifampin (A)
Number of subjects: 150
Study 7808991 — intervention group
Group type: EXPERIMENTAL
Intervention: Two months Rifampin plus Pyrazinamide (B)
Number of subjects: 150
Study 7808991 — intervention group
Group type: COMPARATOR
Intervention: Six months Isoniacid (C)
Number of subjects: 150
Study 7808991 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall compliance across all groups
Number of subjects: 150
Study 7808991 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse effects across all groups
Number of subjects: 150
Study 7808991 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (Two months Rifampin plus Pyrazinamide)
Number of subjects: 150
Study 2782269 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + Nifedipine (10 or 20 mg every 8 hours)
Number of subjects: 12
Study 2782269 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + Diltiazem (60 or 120 mg every 8 hours)
Number of subjects: 12
Study 2782269 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + Nifedipine
Number of subjects: 12
Study 2782269 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + Diltiazem
Number of subjects: 12
Study 31402234 — intervention group
Group type: EXPERIMENTAL
Intervention: PC appointment booked through the booking website prior to ED discharge
Number of subjects: 272
Study 31402234 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information on how to use the booking website
Number of subjects: 272
Study 31402234 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard follow-up instructions)
Number of subjects: 272
Study 31080087 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-laparoscopy
Number of subjects: 40
Study 31080087 — intervention group
Group type: COMPARATOR
Intervention: 2D-laparoscopy
Number of subjects: 40
Study 28422861 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 68
Study 28422861 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 68
Study 28422861 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein (CRP) at biologic introduction
Number of subjects: 68
Study 28422861 — intervention group
Group type: COMPARATOR
Intervention: Age at CD onset
Number of subjects: 68
Study 26718434 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous endometrial cells coculture (AECC)
Number of subjects: 339
Study 26718434 — intervention group
Group type: COMPARATOR
Intervention: Control group (transfer of one embryo on day 3)
Number of subjects: 339
Study 23319447 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (15.4 g of fat)
Number of subjects: 9
Study 23319447 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (4.0 g of fat)
Number of subjects: 9
Study 21422304 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency (1-Hz) 110% motor threshold rTMS to the left temporoparietal junction for 2 weeks
Number of subjects: 14
Study 21422304 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment to the left temporoparietal junction for 2 weeks
Number of subjects: 14
Study 21422304 — intervention group
Group type: COMPARATOR
Intervention: Comparison of active rTMS vs sham treatment
Number of subjects: 14
Study 19186908 — intervention group
Group type: EXPERIMENTAL
Intervention: Leader prototypicality
Number of subjects: 0
Study 19186908 — intervention group
Group type: COMPARATOR
Intervention: Procedural fairness (voice)
Number of subjects: 0
Study 16923629 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-held child health record (PHCHR)
Number of subjects: 309
Study 15207063 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus (RSV)
Number of subjects: 293
Study 15207063 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteroviruses
Number of subjects: 293
Study 15207063 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus
Number of subjects: 293
Study 15207063 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontypable rhino/enterovirus
Number of subjects: 293
Study 15207063 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory picornaviruses (rhinovirus and enteroviruses)
Number of subjects: 293
Study 15207063 — intervention group
Group type: EXPERIMENTAL
Intervention: Human metapneumovirus
Number of subjects: 293
Study 11469927 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day
Number of subjects: 22000
Study 11469927 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg/day
Number of subjects: 22000
Study 11469927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22000
Study 9207358 — intervention group
Group type: EXPERIMENTAL
Intervention: MAC disease (cases)
Number of subjects: 571
Study 9207358 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 571
Study 8133561 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-based ORS (50 g/l)
Number of subjects: 148
Study 8133561 — intervention group
Group type: COMPARATOR
Intervention: Glucose ORS
Number of subjects: 148
Study 8133561 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-based ORS
Number of subjects: 148
Study 3304028 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (400 micrograms/day) for twelve weeks
Number of subjects: 10
Study 3304028 — intervention group
Group type: COMPARATOR
Intervention: Placebo for twelve weeks
Number of subjects: 10
Study 30287612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention game (SAGA) played for 30 minutes, three times a week
Number of subjects: 34
Study 30287612 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 34
Study 27736760 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg intravenous (i.v.) omadacycline
Number of subjects: 24
Study 27736760 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral tablet formulation of omadacycline
Number of subjects: 24
Study 27736760 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral solution of omadacycline
Number of subjects: 24
Study 25461357 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intra-peritoneal wash with lactated Ringer's for 48 hours
Number of subjects: 52
Study 25461357 — intervention group
Group type: COMPARATOR
Intervention: Routine intra-operative irrigation
Number of subjects: 52
Study 22732263 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib alone
Number of subjects: 23
Study 22732263 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus sulindac
Number of subjects: 23
Study 22732263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 20417011 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis (DO) using rigid external distraction (RED) with retention plates
Number of subjects: 13
Study 20417011 — intervention group
Group type: COMPARATOR
Intervention: Le Fort I osteotomy (LF1)
Number of subjects: 13
Study 18701647 — intervention group
Group type: EXPERIMENTAL
Intervention: CMRI vaccine (0.3 to 60 microg followed by a booster dose of 30 microg)
Number of subjects: 0
Study 18701647 — intervention group
Group type: EXPERIMENTAL
Intervention: CMRI vaccine (priming doses)
Number of subjects: 0
Study 18701647 — intervention group
Group type: EXPERIMENTAL
Intervention: CMRI vaccine (after booster dose)
Number of subjects: 0
Study 16081857 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin daily (n=17)
Number of subjects: 38
Study 16081857 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=21)
Number of subjects: 38
Study 12160502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal narcotics (morphine and fentanyl)
Number of subjects: 82
Study 12160502 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (continuous infusion of bupivacaine and fentanyl)
Number of subjects: 82
Study 10432467 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transdermal nicotine patch (22 mg/day)
Number of subjects: 19
Study 10432467 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal nicotine patch
Number of subjects: 19
Study 10432467 — intervention group
Group type: COMPARATOR
Intervention: Both active and placebo patches
Number of subjects: 19
Study 10432467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropouts (not specified intervention)
Number of subjects: 19
Study 10432467 — intervention group
Group type: EXPERIMENTAL
Intervention: Completers (not specified intervention)
Number of subjects: 19
Study 7586920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous theophylline
Number of subjects: 0
Study 7586920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1692755 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 450 mg
Number of subjects: 35
Study 1692755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 7239899 — intervention group
Group type: EXPERIMENTAL
Intervention: hand-warming treatment
Number of subjects: 13
Study 7239899 — intervention group
Group type: COMPARATOR
Intervention: hand-cooling treatment
Number of subjects: 13
Study 31960398 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health care intervention for 12 weeks
Number of subjects: 129
Study 30817090 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage (5 minutes per session, 3 sessions per day, total of 6 sessions over 2 days)
Number of subjects: 90
Study 30817090 — intervention group
Group type: COMPARATOR
Intervention: Control group (no abdominal massage)
Number of subjects: 90
Study 30400684 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 60
Study 30400684 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 60
Study 26037156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine
Number of subjects: 38
Study 26037156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis
Number of subjects: 38
Study 26037156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 24548627 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-α therapy
Number of subjects: 8971
Study 24548627 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-α antibodies (monoclonal and polyclonal)
Number of subjects: 8971
Study 24548627 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies
Number of subjects: 8971
Study 24548627 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyclonal antibodies or receptor blockers
Number of subjects: 8971
Study 24548627 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-α therapy in patients with high levels of IL-6 (> 1000 pg/ml)
Number of subjects: 8971
Study 24548627 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-α therapy in patients with shock
Number of subjects: 8971
Study 22946985 — intervention group
Group type: EXPERIMENTAL
Intervention: Training village volunteers on the use of Paracheck‐Pf® RDT and ACT (artemether‐lumefantrine)
Number of subjects: 38
Study 22946985 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 38
Study 22946985 — intervention group
Group type: COMPARATOR
Intervention: MW group (villages with midwives)
Number of subjects: 38
Study 19589894 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg
Number of subjects: 1207
Study 19589894 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 1207
Study 19589894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study 17558362 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to move the arms out‐of‐phase at each velocity level
Number of subjects: 8
Study 17558362 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to move the arms in‐phase at each velocity level
Number of subjects: 8
Study 17558362 — intervention group
Group type: COMPARATOR
Intervention: No upper extremity phase manipulation
Number of subjects: 8
Study 16885421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle Foot Orthosis (AFO)
Number of subjects: 14
Study 16885421 — intervention group
Group type: EXPERIMENTAL
Intervention: Odstock Dropped-Foot Stimulator (ODFS)
Number of subjects: 14
Study 16885421 — intervention group
Group type: COMPARATOR
Intervention: No device
Number of subjects: 14
Study 16885421 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between AFO and ODFS
Number of subjects: 14
Study 12893845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (0.4 mg/kg)
Number of subjects: 24
Study 12893845 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine cigarette smoking
Number of subjects: 24
Study 12893845 — intervention group
Group type: COMPARATOR
Intervention: Placebo-cocaine
Number of subjects: 24
Study 12893845 — intervention group
Group type: COMPARATOR
Intervention: Low nicotine cigarette smoking
Number of subjects: 24
Study 10821873 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity training
Number of subjects: 54
Study 10821873 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity training
Number of subjects: 54
Study 10821873 — intervention group
Group type: COMPARATOR
Intervention: Control period (12 weeks before training)
Number of subjects: 54
Study 9678128 — intervention group
Group type: EXPERIMENTAL
Intervention: CTR-05 (50/100/150 micrograms desogestrel and 35/30/30 micrograms ethinylestradiol)
Number of subjects: 46
Study 9678128 — intervention group
Group type: COMPARATOR
Intervention: Orthonovum777 (500/750/1000 micrograms norethindrone and 35/35/35 micrograms ethinylestradiol)
Number of subjects: 46
Study 1679916 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% apraclonidine hydrochloride
Number of subjects: 21
Study 6356318 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate (1 g tds 2 h after each meal and 1 g nocte)
Number of subjects: 72
Study 6356318 — intervention group
Group type: COMPARATOR
Intervention: cimetidine (200 mg tds and 400 mg nocte)
Number of subjects: 72
Study 6356318 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 72
Study 6356318 — intervention group
Group type: COMPARATOR
Intervention: cimetidine
Number of subjects: 72
Study 30690053 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused attention condition (attentive eating)
Number of subjects: 34
Study 30690053 — intervention group
Group type: COMPARATOR
Intervention: Control condition (normal eating)
Number of subjects: 34
Study 30290277 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time video counselling
Number of subjects: 0
Study 30290277 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselling
Number of subjects: 0
Study 30290277 — intervention group
Group type: COMPARATOR
Intervention: Written materials (control)
Number of subjects: 0
Study 27162033 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 972
Study 27162033 — intervention group
Group type: COMPARATOR
Intervention: Implanted cardioverter-defibrillator
Number of subjects: 972
Study 27162033 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrandomization AF/AT
Number of subjects: 972
Study 25411141 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ns Q switched Nd YAG laser
Number of subjects: 10
Study 25411141 — intervention group
Group type: COMPARATOR
Intervention: 50 ns Q switched Nd YAG laser
Number of subjects: 10
Study 25411141 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lasers
Number of subjects: 10
Study 22198338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous topotecan 0.5mg/m(2) and cisplatin 30 mg/m(2) given weekly for 6 weeks with pelvic radiation
Number of subjects: 11
Study 22198338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous topotecan 0.5mg/m(2) and cisplatin 40 mg/m(2) given weekly for 6 weeks with pelvic radiation
Number of subjects: 11
Study 22198338 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 30 mg/m(2) in combination with topotecan 0.5mg/m(2) and pelvic radiation
Number of subjects: 11
Study 19443125 — intervention group
Group type: EXPERIMENTAL
Intervention: Framycetin 1% cream (Soframycin)
Number of subjects: 40
Study 19443125 — intervention group
Group type: COMPARATOR
Intervention: Silver sulphadiazine
Number of subjects: 40